4.7 Article

Glycaemia and body weight are regulated by sodium-glucose cotransporter 1 (SGLT1) expression via O-GlcNAcylation in the intestine

Journal

MOLECULAR METABOLISM
Volume 59, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.molmet.2022.101458

Keywords

Intestine; O-GlcNAcylation; SGLT1; Glucose absorption; GLP-1

Funding

  1. Japan Society for the Promotion of Science [18H02862, 19K08998]
  2. Shiga University of Medical Science
  3. Nipro
  4. Bayer Yakuhin
  5. Boehringer-Ingelheim
  6. Kyowa Hakko Kirin
  7. Kowa Pharmaceuticals
  8. Sumitomo Dainippon Pharma Co., Ltd.
  9. DaiichiSankyo
  10. Takeda Pharmaceutical Company Limited
  11. Novo Nordisk Pharma
  12. Mitsubishi Tanabe
  13. Sanwa Kagaku Kenkyusho
  14. MSD
  15. Mochida Pharmaceutical Co., Ltd.
  16. Grants-in-Aid for Scientific Research [19K08998, 18H02862] Funding Source: KAKEN

Ask authors/readers for more resources

Loss of O-GlcNAcylation in the intestine reduces glucose absorption by suppressing SGLT1 expression. This study provides new insights into the role of O-GlcNAcylation in glucose metabolism and suggests potential treatments for malabsorption, obesity, and diabetes.
Objective: The intestine is an important organ for nutrient metabolism via absorption and endocrine systems. Nutrients regulate O-GlcNAcy-lation, a post-translational modification of various proteins by O-GlcNAc transferase (OGT). We have previously shown that general OGT knockout induced severe weight loss and hypoglycaemia in mice, but little is known about how O-GlcNAcylation in the intestine modulates nutrient metabolism, especially glucose metabolism, through absorption. We aimed to reveal the roles of O-GlcNAcylation in glucose absorption by the small intestine and elucidate the mechanism by which O-GlcNAcylation regulates sodium-glucose cotransporter 1 (SGLT1) expression.& nbsp;Methods: First, we fasted normal mice and examined the changes in glucose transporters and O-GlcNAcylation in the intestine. Then, we generated two lines of small intestine-specific OGT-deficient mice (congenital: Ogt-VKO, tamoxifen-inducible: Ogt-iVKO) and observed the changes in body weight and in glucose and lipid metabolism. Finally, we investigated Sglt1 gene regulation by O-GlcNAcylation using enter-oendocrine STC-1 cells.& nbsp;Results: Fasting decreased O-GlcNAcylation in the intestinal epithelium of normal mice. The Ogt-VKO mice showed significantly lower non-fasted blood glucose levels and were underweight compared with litter matched controls. Glycaemic excursion in the Ogt-VKO mice was significantly lower during the oral glucose tolerance test but comparable during the intraperitoneal glucose tolerance test. Furthermore, the Ogt-VKO mice exhibited lower Sglt1 expression in the small intestine compared with the control mice. We obtained similar results using the Ogt-iVKO mice only after tamoxifen administration. The oral D-xylose administration test revealed that the intestinal sugar absorption was diminished in the Ogt-iVKO mice and that GLP-1 secretion did not sufficiently increase after glucose gavage in the Ogt-iVKO mice. When using STC-1 cells, O-GlcNAcylation increased Sglt1 mRNA via a PKA/CREB-dependent pathway.Conclusion: Collectively, loss of O-GlcNAcylation in the intestine reduced glucose absorption via suppression of SGLT1 expression; this may lead to new treatments for malabsorption, obesity and diabetes. (C)& nbsp;2022 The Author(s). Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available